3,637 patients — but retrospective telehealth data can't separate dose from expectancy.
Weekly Science Digest, 13 Nov 2026 to 19 Nov 2026. 30 papers read, 12 preprints, 1 new trials.
1. Does the experience matter? Two more attempts
Stronger subjective effects went with better depression outcomes across 3,637 ketamine patients.
In a telehealth programme giving up to four sublingual doses over four weeks, pre-registered analyses found higher scores on a five-item psychedelic intensity scale at week two predicted greater PHQ-9 improvement. A separate chart review of 51 esketamine patients found trait dissociation tracked baseline depression severity and was elevated in those with trauma comorbidity.
How much weight it carries: Large pre-registered analysis of an existing telehealth cohort; shows association between rated intensity and symptom change, not that the experience causes the benefit. (Humans, Observational, Retrospective, Industry, No control group, n = 3,637)
2. Mescaline raises empathy, and ketanserin blocks it
A 5-HT2A antagonist abolished mescaline's empathy effect in a 16-person crossover study.
Healthy volunteers received placebo, four mescaline doses from 100 to 800 mg, and 800 mg plus 40 mg ketanserin, double-blind and in random order. Emotional empathy rose on mescaline and the receptor blocker took it away, alongside measured plasma oxytocin.
How much weight it carries: Well-controlled crossover with an antagonist arm, but 16 healthy volunteers and an acute laboratory measure with no clinical endpoint. (Humans, Double-blind, Placebo-controlled, Controlled, Small sample, Mechanism, n = 16)
High-dose psilocybin blocked CGRP signalling and slowed head and neck tumour growth in mice.
Cutting sensory nerve signalling reduced tumour growth in orthotopic models, and CGRP knockout plus radioimmunotherapy eradicated tumours. Psilocybin acted on the same pathway, transiently shrinking tumours by boosting antitumour immunity, with plasma correlations from single-dose human subjects.
How much weight it carries: Mouse tumour models plus in vitro work, with a correlational human plasma analysis; no clinical evidence that psilocybin affects cancer outcomes. (Mice, Preclinical, Mechanism, In vitro, Review)
Five Swiss labs quantified LSD blotters to within 8-16.5% of each other, slightly under the true value.
The interlaboratory ring trial used three different analytical techniques across services and corrected results against qNMR-verified reference standard. Variability was larger for the liquid sample, and mean accuracy ran 5-13% low.
How much weight it carries: Analytical ring trial across five labs on three samples; speaks to measurement reliability only, with the poison centre data retrospective and regional. (Observational, Retrospective)